Prediction of Alzheimer's disease progression within 6 years using speech: A novel approach leveraging language models
- PMID: 38924662
- PMCID: PMC11350035
- DOI: 10.1002/alz.13886
Prediction of Alzheimer's disease progression within 6 years using speech: A novel approach leveraging language models
Abstract
Introduction: Identification of individuals with mild cognitive impairment (MCI) who are at risk of developing Alzheimer's disease (AD) is crucial for early intervention and selection of clinical trials.
Methods: We applied natural language processing techniques along with machine learning methods to develop a method for automated prediction of progression to AD within 6 years using speech. The study design was evaluated on the neuropsychological test interviews of n = 166 participants from the Framingham Heart Study, comprising 90 progressive MCI and 76 stable MCI cases.
Results: Our best models, which used features generated from speech data, as well as age, sex, and education level, achieved an accuracy of 78.5% and a sensitivity of 81.1% to predict MCI-to-AD progression within 6 years.
Discussion: The proposed method offers a fully automated procedure, providing an opportunity to develop an inexpensive, broadly accessible, and easy-to-administer screening tool for MCI-to-AD progression prediction, facilitating development of remote assessment.
Highlights: Voice recordings from neuropsychological exams coupled with basic demographics can lead to strong predictive models of progression to dementia from mild cognitive impairment. The study leveraged AI methods for speech recognition and processed the resulting text using language models. The developed AI-powered pipeline can lead to fully automated assessment that could enable remote and cost-effective screening and prognosis for Alzehimer's disease.
Keywords: Alzheimer's disease prognosis; Framingham Heart Study; natural language processing; neuropsychological test.
© 2024 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Conflict of interest statement
Rhoda Au is a scientific advisor to Signant Health and NovoNordisk and consultant to Biogen and the Davos Alzheimer's Collaborative. She receives funding from the National Institute on Aging (AG072654, AG062109, AG068753) and has also been supported through awards from the American Heart Association, the Alzheimer's Drug Discovery Foundation, Alzheimer's Disease Data Initiative, and Gates Ventures. Vijaya B. Kolachalama has received support from the Karen Toffler Charitable Trust; Johnson & Johnson (through the Boston University Lung Cancer Alliance); the NIH under grants RF1‐AG062109, R01‐HL159620, R43‐DK134273, and R21‐CA253498; the American Heart Association under grant 20SFRN35460031; and serves as a consultant to AstraZeneca. Both R. Au and V. B. Kolachalama state no conflicts of interest with the present work. There is no declaration from other authors. Author disclosures are available in the supporting information.
Figures
References
-
- Mitchell AJ, Shiri‐Feshki M. Rate of progression of mild cognitive impairment to dementia–meta‐analysis of 41 robust inception cohort studies. Acta Psychiatr Scand. 2009;119:252‐265. - PubMed
-
- Liu S, Cao Y, Liu J, Ding X, Coyle D, Initiative ADN. A novelty detection approach to effectively predict conversion from mild cognitive impairment to Alzheimer's disease. Int J Mach Learn Cybern. 2023;14:213‐228.
-
- Scheltens P, Blennow K, Breteler M, et al. Alzheimer's disease. Lancet (Lond Engl). 2016;388:505‐517. - PubMed
Publication types
MeSH terms
Grants and funding
- R01 AG016495/AG/NIA NIH HHS/United States
- R01 GM135930/GM/NIGMS NIH HHS/United States
- RF1 AG062109/AG/NIA NIH HHS/United States
- DMS-1664644/NSF
- AG16495/AG/NIA NIH HHS/United States
- AG072654/AG/NIA NIH HHS/United States
- AG068753/AG/NIA NIH HHS/United States
- AG008122/AG/NIA NIH HHS/United States
- IIS-1914792/NSF
- U19 AG068753/AG/NIA NIH HHS/United States
- CCF-2200052/NSF
- UL54 TR00413/GF/NIH HHS/United States
- RF1 AG072654/AG/NIA NIH HHS/United States
- R01 GM135930/GF/NIH HHS/United States
- R01 AG008122/AG/NIA NIH HHS/United States
- N01-HC-25195/HL/NHLBI NIH HHS/United States
- R56 AG062109/AG/NIA NIH HHS/United States
- AG062109/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
